SCHEMBL20074230

SCHEMBL20074230

CC(C)c1c(-c2cnn(-c3cccc(Cl)c3)c2)[nH]c2ncnn2c1=O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 9/20 0.57
KDM5A P29375 1/20 0.39
MKNK1 Q9BUB5 2/20 0.37
TSHR P16473 1/20 0.34
GRM4 Q14833 1/20 0.34
MAPK10 P53779 1/20 0.33
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33
DAPK3 O43293 1/20 0.33
PIM1 P11309 1/20 0.33
DAPK1 P53355 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
DAPK2 Q9UIK4 1/20 0.33
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20074324 0.89 KDM5B (0.53) KDM5BKDM5ATSHRGRM4MEN1
SCHEMBL21721750 0.85 KDM5B (0.49) KDM5BTSHRMEN1HPGDKMT2A
SCHEMBL31676999 0.85 KDM5B (0.49) KDM5BTSHRMEN1HPGDKMT2A
SCHEMBL21681718 0.83 KDM5B (0.54) KDM5BKDM5ATSHRGRM4HPGD
SCHEMBL20074303 0.79 CCNB2 (0.47) KDM5BKDM5ATSHRMEN1HPGD
SCHEMBL31676984 0.78 KDM5B (0.55) KDM5BTSHRLMNA
SCHEMBL20074314 0.78 KDM5B (0.55) KDM5BTSHRLMNA
SCHEMBL21721735 0.78 KDM5B (0.47) KDM5BKDM5ATSHR
SCHEMBL20074323 0.77 KDM5B (0.56) KDM5B
SCHEMBL21681711 0.77 KDM5B (0.48) KDM5BKDM5ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP claimed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US claimed
US-20200048258-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 US claimed
EP-3525785-B1 KDM5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-08-27 EP disclosed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US disclosed
US-10975084-B2 KDM5 inhibitors MERCK SHARP & DOHME CORP. (US) 2021-04-13 US disclosed
US-20200048258-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 US disclosed
US-20200048258-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-02-13 US disclosed
WO-2018071283-A1 KDM5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048258-A1 KDM5 INHIBITORS KDM5A, KDM5B, KDM5C KDM5B 2/4885KDM5A 1/4885MKNK1 404/4885
US-10975084-B2 KDM5 inhibitors KDM5A, KDM5B, KDM5C KDM5B 2/4885KDM5A 1/4885MKNK1 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.